TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:28
Evelo Biosciences Inc. ( EVLO ) https://www.evelobio.com
0.05USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-98.79%
EVLO
SPY
32.74%
-99.98%
EVLO
SPY
92.93%
-99.97%
EVLO
SPY
224.41%
EVLO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.06
-9.28
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.01
0.00
-0.04
-7022.11
0.00
0.14
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.984
-121.56
-271.83
1.80
Other Earnings and Cash Flow Stats:
Evelo Biosciences Inc. ( EVLO ) Net Income TTM ($MM) is -91.81
Evelo Biosciences Inc. ( EVLO ) Operating Income TTM ($MM) is -86.22
Evelo Biosciences Inc. ( EVLO ) Owners' Earnings Annual ($MM) is 0.00
Evelo Biosciences Inc. ( EVLO ) Current Price to Owners' Earnings ratio is 0.00
Evelo Biosciences Inc. ( EVLO ) EBITDA TTM ($MM) is -84.92
Evelo Biosciences Inc. ( EVLO ) EBITDA Margin is 0.00%
Capital Allocation:
Evelo Biosciences Inc. ( EVLO ) has paid 0.00 dividends per share and bought back -13.025809 million shares in the past 12 months
Evelo Biosciences Inc. ( EVLO ) has reduced its debt by 46.475 million USD in the last 12 months
Capital Structure:
Evelo Biosciences Inc. ( EVLO ) Interest-bearing Debt ($MM) as of last quarter is 6
Evelo Biosciences Inc. ( EVLO ) Annual Working Capital Investments ($MM) are 26
Evelo Biosciences Inc. ( EVLO ) Book Value ($MM) as of last quarter is -27
Evelo Biosciences Inc. ( EVLO ) Debt/Capital as of last quarter is -26%
Other Balance Sheet Stats:
Evelo Biosciences Inc. ( EVLO ) has 17 million in cash on hand as of last quarter
Evelo Biosciences Inc. ( EVLO ) has 39 million of liabilities due within 12 months, and long term debt 33 as of last quarter
Evelo Biosciences Inc. ( EVLO ) has 17 common shares outstanding as of last quarter
Evelo Biosciences Inc. ( EVLO ) has 0 million USD of preferred stock value
Academic Scores:
Evelo Biosciences Inc. ( EVLO ) Altman Z-Score is -51.80 as of last quarter
Evelo Biosciences Inc. ( EVLO ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Evelo Biosciences Inc. ( EVLO ) largest shareholder is Tower Research Capital LLC owning 3453 shares at 0.00 ($MM) value
Simba Gill(an insider) Sold 172 shares of Evelo Biosciences Inc. ( EVLO ) for the amount of $56.76 on 2023-11-08
0.23% of Evelo Biosciences Inc. ( EVLO ) is held by insiders, and 83.14% is held by institutions
Evelo Biosciences Inc. ( EVLO ) went public on 2018-05-09
Other Evelo Biosciences Inc. ( EVLO ) financial metrics:
FCF:-76.76
Unlevered Free Cash Flow:-92.30
EPS:-2.84
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:185.18
Beta:1.80
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Evelo Biosciences Inc. ( EVLO ) :
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.